Epizyme (EPZM) Stock Price, News & Analysis

Company Overview

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.47 to $1.47
• 50-Day Range: $1.47 to $1.52
• 52-Week Range: $0.41 to $5.80
• Volume: 7,960 shs
• Average Volume: 3.23 million shs
• Market Capitalization: $247.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Epizyme Stock Analysis - MarketRank™

Epizyme scored higher than 27% of companies evaluated by MarketBeat, and ranked 840th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Epizyme.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Epizyme are expected to grow in the coming year, from ($1.34) to ($1.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Epizyme is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Epizyme is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for EPZM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Epizyme does not currently pay a dividend.

Dividend Growth

Epizyme does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.07

Short Interest

There is no current short interest data available for EPZM.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for EPZM on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Epizyme insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.40% of the stock of Epizyme is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.45% of the stock of Epizyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EPZM Stock Analysis - Frequently Asked Questions

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.16. Epizyme's quarterly revenue was up 45.8% compared to the same quarter last year.

What other stocks do shareholders of Epizyme own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Epizyme investors own include Novavax (NVAX), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Applied Materials (AMAT) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 1/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EPZM
• CUSIP: N/A
• CIK: 1571498
• Web: www.epizyme.com
• Phone: (617) 229-5872
• Fax: 617-349-0707
• Employees: 250
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-251,120,000.00
• Net Margins: -391.90%
• Pretax Margin: -391.80%
• Return on Equity: -2,459.33%
• Return on Assets: -69.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.35
• Quick Ratio: 5.19

Sales & Book Value

• Annual Sales: $37.43 million
• Price / Sales: 6.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.54) per share
• Price / Book: -2.72

Miscellaneous

• Outstanding Shares: 168,329,000
• Free Float: 128,968,000
• Market Cap: $247.44 million
• Optionable: Optionable
• Beta: -0.41